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Abstract
Background: Information is lacking on the effects of congenital toxoplasmosis on development, behavior,
and impairment in later childhood, as well as on parental concerns and anxiety. This information is
important for counselling parents about the prognosis for an infected child and for policy decisions on
screening.
Methods: We prospectively studied a cohort of children identified by screening for toxoplasmosis in
pregnant women or neonates between 1996 and 2000 in ten European centers. At 3 years of age, parents
of children with and without congenital toxoplasmosis were surveyed about their child's development,
behavior, and impairment, and about parental concerns and anxiety, using a postal questionnaire.
Results: Parents of 178/223 (80%) infected, and 527/821 (64%) uninfected children responded. We found
no evidence that impaired development or behavior were more common in infected children, or that any
potential effect of congenital toxoplasmosis was masked by prenatal treatment. Parents of infected
children were significantly more anxious and reported more visual problems in their children.
Conclusion: On average, children aged three to four years with congenital toxoplasmosis identified by
screening and treated during infancy in this European setting had risks of abnormal development and
behavior similar to uninfected children. Parental anxiety about infected children needs to be addressed by
clinicians. Future studies with longer follow up and clinician-administered assessments may be better able
to detect any subtle differences in child outcomes.
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Congenital toxoplasmosis is associated with a wide spec-
trum of clinical signs and symptoms. At its most severe,
congenital toxoplasmosis causes death or severe disability
in 1–4% of infants identified by prenatal or neonatal
screening[1]. Although the remaining 96% of infected
infants appear clinically normal in infancy, one in six have
intracranial and/or ocular lesions. Clinicians lack infor-
mation for counselling parents about their child's func-
tional abilities in later childhood, and whether
intracranial or ocular lesions predict adverse functional
outcomes. In addition, policy makers need to know what
proportion of children with congenital toxoplasmosis suf-
fer long term functional impairment. However, a system-
atic search of the literature found only one study of
children identified by screening in which school perform-
ance in 11 infected children was compared with their
peers at 7 years[2]. No difference was found but this may
be due to the sample size and/or the insensitivity of the
outcome measure. Other studies of developmental out-
comes have been based on case series of referred and usu-
ally symptomatic children with congenital toxoplasmosis,
and have not included an appropriate comparison
group[3,4].
We wanted to know whether 3-year-old children with
congenital toxoplasmosis are more at risk of adverse
developmental or behavioral outcomes than uninfected
children. We also investigated parental concerns and anx-
iety as clinicians caring for infected children highlighted
parental anxiety as a common clinical problem. We con-
ducted a prospective cohort study of children identified
by prenatal or neonatal screening for toxoplasmosis.
Infected and uninfected children born to infected women
were followed up during infancy and then surveyed using
a parent-completed questionnaire to assess development
and other outcomes when the child turned 3 years. This
design aimed to ensure that, apart from congenital infec-
tion status, the experience of screening, and follow up in
early infancy, was similar. However, only infected chil-
dren received prolonged postnatal treatment and follow
up.
Methods
Study population
We compared children, with and without congenital tox-
oplasmosis, born to women identified by prenatal screen-
ing for maternal toxoplasmosis between 1996 and 2000
in eight centers (Lyon, Paris, Marseille, Toulouse, Nice,
Grenoble, Vienna, and Naples), and by neonatal screen-
ing in two centers (Stockholm, Poznan). One other
center, Denmark, was excluded from the analyses as no
uninfected children were recruited. Details of the methods
have been reported elsewhere [5,6]. In brief, 91% of the
women in the prenatal screening centers[6], but none in
the neonatal screening centers, received anti-toxoplasma
treatment before birth. In Poznan (Poland), children were
identified by universal neonatal screening for specific IgM
in filter paper blood spots from the Guthrie card and
uninfected controls were selected as the next six children
with a negative screening test born after each infected
child[5].
Clinical follow up
Women suspected to have acquired toxoplasma infection
during pregnancy and infected infants identified by neo-
natal screening were enrolled prospectively, prior to the
collection of follow up data. We used a standard question-
naire to record clinical findings during pregnancy, at pedi-
atric examinations in the neonatal period, at six and 12
months, and at ophthalmoscopy before four months and
at 12 months of age. Cranial ultrasound was performed
within the first four months of life. The number of exam-
inations (pediatric, ophthalmic, and cranial ultrasound)
was similar in infected and uninfected children up to 4
months of age.
Confirmation of congenital infection status was based on
the persistence of IgG antibodies after 11.5 months of age
(infected), or undetectable specific IgG antibodies in the
absence of treatment, which usually occurred between 8
and 12 months[6]. To avoid potential biases due to exclu-
sion of 15% of infants who did not meet these confirma-
tory criteria, we used probability estimations of their
congenital infection status based on PCR analysis of
amniotic fluid, specific IgM or IgA in the infant, last avail-
able IgG results, and the weeks of gestation at maternal
seroconversion[6]. All infected children received treat-
ment from early infancy for 12 to 24 months, depending
on the centre, based on the results of prenatal diagnosis,
and/or a positive IgM/IgA test, or a lack of decline in spe-
cific IgG titers. The median age at the start of postnatal
treatment in prenatal centers was 2 days (IQR: 0, 14), and
in neonatal screening centers 26 days (IQR: 22, 33). Few
uninfected children were treated postnatally. As prenatal
treatment after fetal diagnosis, and postnatal treatment,
were given predominantly to those with evidence of con-
genital infection, postnatal treatment could not be inves-
tigated in this analysis. In Poznan, the uninfected children
had no involvement in the cohort until their parents were
sent a questionnaire when they turned 3 years. As no clin-
ical follow up information was available for these chil-
dren, they are excluded from analyses of children with no
signs or symptoms in infancy.
We included all children identified by prenatal or neona-
tal screening in the parent-questionnaire study at 3 years,
with some exceptions. First, in Austria and Italy, we ran-
domly selected 4 uninfected children for each infected
child, stratified by year of birth, to avoid surveyingPage 2 of 10
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child in these centers. Second, to minimize potential
selection biases, we excluded children with non-sequen-
tial dates for the detection of maternal infection, fetal
infection or abnormality, or, in the neonatal centre, for
screening and confirmatory tests, as these women or chil-
dren may have been referred. Third, 21 infected children
known to be lost to follow up were not surveyed (4 died,
but no serious outcomes were documented by paediatri-
cians in the remainder).[7] Fourth, two centers participat-
ing in the initial cohort[6] did not participate in the 3 year
follow up (Reims, Milan), and one did not enroll unin-
fected controls (Copenhagen). A detailed description and
evaluation of questionnaire response has been reported
elsewhere.[7] In brief, the questionnaire was composed of
separate assessment tools (in total or in part) for behavior,
speech and language, cognition, and motor skills, that
have been previously validated against clinician assess-
ments[7]. To-date the questionnaire as a whole has not
been validated with standardized clinician assessments.
The postal questionnaire, with a stamped addressed enve-
lope for reply, and crayons for the child, was sent to par-
ents by the local study centre when the child turned 3
years. Non-responders were sent two reminders at 2-
monthly intervals. Research Ethics approval was obtained
for all participating centres.
Outcomes
The results for the effect of congenital toxoplasmosis and
potential confounders are presented for three groups of
outcomes. The first comprised developmental outcomes
(gross motor, speech and language, and cognitive), and
abnormal behavior. These were measured by questions
derived from standardized tools that had been validated
against clinician assessments[7]. The questionnaire also
included two child-completed sections that assessed cog-
nitive and fine motor development. Children were asked
to copy a line, circle and cross, drawn by their parent, and
secondly, to draw a man[8]. Child-completed measures
were analyzed separately from parent-completed meas-
ures because not all children participated, and we could
not standardize the degree of assistance given to the child.
The second group of outcomes measured parental con-
cerns about development, learning, behavior, and speech
and language, specialist referral, and asked parents to rate
how worried they were about their child's general health
at the time and in the future[9]. Parental concerns about
specific areas of development, or specialist referral may be
proxy markers of abnormal development[10,11]. More
general anxiety about the child's health now and in the
future may reflect anxiety generated by diagnosis, treat-
ment and follow up[9], but may also be a marker for
abnormality. The third group of outcomes comprised spe-
cific impairments that parents were asked about, includ-
ing difficulty hearing or seeing, and whether the child had
cerebral palsy or seizures. The primary outcomes were the
scores for motor development, speech and language, cog-
nition, and behaviour, and parental anxiety.
Analyses
We aimed to compare infected and uninfected children,
stratified by centre because of differences in screening pro-
grams and treatment regimens, and possible differences in
expectations and attitudes to congenital toxoplasmosis.
There was also significant variation among centers for
exposure and outcome variables. We therefore present the
preliminary bivariate analyses to show the effect of centre
on outcomes, and adjust all subsequent analyses for
center, nested within country, and congenital infection
status. Stockholm and Naples were grouped as one centre,
due to small numbers. Outcome variables were defined by
a score measured on an interval scale (further details
reported elsewhere[6]. Abnormality was defined by a cut-
point approximating the least able 10% of controls, or for
behavior, using an established cut point for abnormality
(equivalent to 10% in a large community sample in which
the questionnaire was validated[12]). Missing data for
mother's age was imputed using a procedure for both con-
tinuous and categorical variables[13]
Multivariate analyses of the effect of congenital toxoplas-
mosis included centre nested within country, maternal
education, and child's age at questionnaire completion, in
every model based on evidence of confounding in some
comparisons and consensus among investigators as to
their clinical relevance. We included other potential con-
founders with p values = 0.20 from the bivariate analy-
ses[14], but retained those variables with p-values <0.05
in the final model. Where the effect of congenital toxo-
plasmosis was significant (= 0.05), we tested for an inter-
action between centre and infection status. We used a
hierarchical generalized linear model to account for heter-
ogeneity among centres within France and between cen-
tres inside and outside France[15] A generalized
estimating equation (SAS Version 9.1 PROC GENMOD
with the ASSESS options to assess fit of the model) with
centers nested within country was derived to determine
characteristics associated with each dichotomized out-
come. Odds ratios were derived by exponentiating param-
eter estimates, as well as lower and upper bounds for
corresponding 95% confidence intervals. For logistic
regression, Wald estimates were used.
We performed several sensitivity analyses for the associa-
tion between congenital toxoplasmosis and development
and behavior, and parental concerns and anxiety, and spe-
cialist referral. First, to avoid spurious associations due to
dichotomization of outcomes, we repeated the main anal-
yses using ordinal logistic regression for all outcomesPage 3 of 10
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guage, and cognitive development, behavior, child com-
pleted drawings, impact of behavior on family, and
parental anxiety). Second, for the main model with
dichotomized outcomes primary analyses using country
as a fixed effect, were repeated using a generalized mixed
model approach with country as a random effect Second,
to test whether the effect of congenital toxoplasmosis on
outcomes differed across countries, we derived separate
multivariate models for each country. Third, to minimize
the confounding effect of child's age at questionnaire
completion on developmental outcomes, we restricted
analyses to children aged 36 to 40 months. Fourth, to
minimize confounding due to clinical manifestations
detected in early infancy, we restricted analyses to chil-
dren who had no clinical signs identified by the first 4
months of life. Signs were defined as intracranial calcifica-
tion or ventricular dilatation on ultrasound, retinoc-
horoiditis, lymphadenopathy or hepatosplenomegaly,
microphthalmia, microcephaly, seizures, or an abnormal
neurological examination. These analyses excluded
Poland, where uninfected children were not assessed by
the study during infancy. Fifth, to determine whether the
duration of prenatal treatment may have masked an effect
of congenital toxoplasmosis, we analyzed the effect of
congenital toxoplasmosis, adjusted for prenatal treatment
duration, and gestational age at maternal seroconversion,
in French women who seroconverted during pregnancy.
In these women, the gestational age at seroconversion
could be estimated fairly precisely based on the midpoint
between a negative and positive specific IgM test (usually
a one month interval), or 14 days before a positive specific
IgM result and negative IgG result[16]. Finally, to detect
any adverse effects of prenatal treatment, we confined
analyses to uninfected children, using the same approach
as for the main model.
Without taking into account adjustment for confounders,
the study was designed to have 80% power to detect a
minimum difference of 0.22 standard deviations, assum-
ing 70% response in the controls, 80% response in
infected children, and an alpha error of 0.05.
Results
Study population
Of the 1044 families sent a questionnaire in 10 centers,
parents of 178/223 (80%) infected, and 527/821 (64%)
uninfected children responded. The distribution of
infected and uninfected children by centre was: Lyon (40,
94), Paris (41,50), Marseille (18, 51), Nice (5, 28), Tou-
louse (18, 26), Vienna (18, 116), Stockholm (2, 6),
Naples (10, 40), Poznan (23, 111). Details about factors
associated with response, reasons for non-response, and
exclusions due to death or potential referral bias, are
reported elsewhere7. Most parents completed the entire
questionnaire, as shown by the denominator for each out-
come in Table 1. However, far fewer children completed
the drawings: 70% (493/705) completed the draw a man
test; and 95% (670/705) copied a line, circle or cross. Few
parents reported neurological problems or impaired
mobility (N = 6), but visual impairment (n = 10), and
hearing loss was more common (N = 37).
Potential confounders
The results for the associations between exposures and the
three groups of outcomes are shown in Tables 2,3 and 4,
adjusted for center and congenital infection status. Mater-
nal age and education level, and child's age at question-
naire completion had significant effects on parent-
reported developmental outcomes (Table 2), but not on
parental concerns and anxiety (Table 3), or specific
impairments (Table 4). Adverse cognitive development
was reported more commonly in Grenoble compared
with Lyon, and behavior problems were reported more
commonly in Marseille. There were significant associa-
tions between congenital infection status and parental
anxiety (Table 3). Parents in Poznan, reported more anxi-
ety than in Lyon, and children in Poznan, and Stockholm/
Naples were more likely to be referred to a specialist.
There were more parental concerns about children in
Poznan than in Lyon, and about girls than boys. Table 4
shows that visual impairment was more common in
infected children, and was reduced in children with longer
duration of prenatal treatment. Hearing loss appeared to
be less common with increasing parity.
Information on clinical signs before four months of age
was available for 571 children (excluding 23 infected and
111 uninfected children in Poznan). 131/155 (85%)
infected children and 407/414 (98%) uninfected children
had no clinical signs. In the remainder, clinical manifesta-
tions were detected before four months of age in order of
increasing severity: lymphadenopathy or hepatosplenom-
egaly (3 infected, 2 uninfected); retinochoroiditis alone (6
infected, 0 uninfected); intracranial lesions, with or with-
out retinochoroiditis (13 infected, 3 uninfected); and
neurological impairment, with or without ocular or
intracranial lesions and including seizures, microcephaly,
microphthalmia, or abnormal neurological examination
(2 infected, 4 uninfected).
Multivariable analyses
Development and behavior
There was no significant association between congenital
infection status and abnormal development or behavior
(Table 5). Similar results were obtained in the sensitivity
analyses. In analyses confined to France, there was no evi-
dence that an adverse effect of congenital infection status
was masked by the duration of prenatal treatment, or thatPage 4 of 10
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children (results not shown).
Parental concerns, specialist referral, and parental anxiety
Significantly more anxiety was reported in parents of
infected than uninfected children. Overall the risk of hav-
ing a high anxiety score was more than doubled for par-
ents of infected children in all centers. Not surprisingly,
the risk was more than trebled in Poland, where parents
of infected children were compared with parents from the
general population who had not been identified by
screening. The association between congenital infection
status and parental anxiety was attenuated and no longer
significant in analyses confined to France. None of these
results changed appreciably when analyses were repeated
using ordinal regression. There was no evidence that dura-
tion of prenatal treatment either masked an effect of con-
genital infection status on parental concerns, referrals, or
anxiety, or had an adverse effect on these outcomes in
uninfected children (results not shown, but available
from authors).
Parent- reported impairment
The risk of visual impairment was doubled in infected vs
uninfected children (p = .024). This was mainly due to an
increased risk of limited vision, affecting 7 infected and 3
uninfected children. There was no significant difference in
the proportion of children wearing glasses at 3 years
(6.8% infected, 4.2% uninfected; p = 0.17). Hearing
impairment was more common in uninfected children
but this association was not significant. The risk of neuro-
logical or mobility problems was higher in infected chil-
dren, but not significant at the 5% level as this outcome
was reported for only 6 children.
Discussion
Congenital toxoplasmosis was associated with increased
parental anxiety about the child's health now and in the
future, and with an increased risk of visual impairment.
The magnitude of the effect of congenital toxoplasmosis
on parental anxiety was reduced in France. We found no
evidence for an association between congenital toxoplas-
mosis and other markers of adverse development or
behavior at three years.
Table 1: Number of children with an adverse outcome according to congenital infection status (%)
1) DEVELOPMENT AND BEHAVIOUR
PARENT COMPLETED
Infection status Motor1 Speech & language1 Behaviour2 Cognition1
CT+ (n = 178) 24/178 (13.5) 20/177 (11.3) 34/176 (19.3) 9/178 (5.1)
CT- (n = 527) 58/525 (11.0) 50/524 (9.5) 97/527 (18.4) 31/525 (5.9)
CHILD COMPLETED
Infection status 'Draw a Man'1 Line, circle, cross1
CT+ (n = 178) 17/121(14.0) 13/170(7.6)
CT- (n = 527) 54/372(14.5) 38/500(7.4)
2) PARENTAL CONCERNS, SPECIALIST REFERRAL, AND PARENTAL ANXIETY
CONCERNS
Learning/ development3 Speech & language3 ANY3
CT+ (n = 178) 24/176(13.6) 16/177(9.0) 34/178(19.1)
CT- (n = 527) 53/522(10.2) 55/522(10.5) 79/527(15.0)
REFERRALS
Learning/ development Speech & language ANY Behaviour impact 2 Parental anxiety1
CT+ (n = 178) 10/178(5.6) 4/178(2.3) 11/178(6.2) 3/173 (1.7) 41/176 (23.3)
CT- (n = 527) 13/527(2.5) 14/527(2.7) 20/527(3.8) 16/509 (3.1) 61/521 (11.7)
3) PARENT-REPORTED IMPAIRMENT
VISUAL IMPAIRMENT
Glasses only Strabismus/ blind/limited vision ANY Hearing loss4 Neurological/
mobility impairment5
CT+ (n = 178) 5 10 15/177 (8.5) 7/166 (4.2) 2/175 (1.1)
CT- (n = 527) 11 13 24/527 (4.6) 30/498(6.0) 4/522 (0.8)
Full questionnaire available from the EMSCOT website [22]
CT = congenital toxoplasmosis
1Adverse outcome defined by score corresponding most closely to the least able/most worried 10% in the uninfected children
2Adverse outcome defined by developers of SDQ questionnaire. Equivalent to lowest 10% in community sample of 10,000 examined in evaluation 
study. [12]
3Defined by answering 'yes' or 'a little' to question(s) about concerns.
4Parents reported intermittent or permanent hearing loss
5Parents reported seizures requiring treatment, cerebral palsy, and/or impaired mobilityPage 5 of 10
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during the design of the study, that parental anxiety was
one of the most common problems encountered. An
alternative interpretation, is that the association was a
chance finding, arising because of the multiple compari-
sons performed. However, the consistency of the finding
in sensitivity analyses, and with prior observation, make
this explanation unlikely.
Other studies of children identified by screening have
similarly reported that infected children appear to be
developmentally normal, but no studies have systemati-
cally assessed development[2,17]. In contrast, the risk of
neurological impairment is much higher in case series of
referred children identified because of symptoms or
abnormalities. For example, in the Chicago study, 13/45
(29%) children had an IQ/DQ score less than 85 (equiv-
alent to one standard deviation below the mean) at 1 or 3
years old[4]. In a further case series reported by Wilson et
al, 8/13 referred children had low (<50) or declining IQ/
DQ scores at a mean age of 5.5 years[3].
A strength of the study is the minimization of selection
bias due to referral of affected fetuses or children, by
requiring that screening tests predated investigations for
abnormality. As this study was prospective, data on clini-
cal manifestations in infancy, could not be biased by the
child's condition at 3 years. Conversely, we investigated
Table 2: Factors associated with development and behaviour at 3 years, adjusted for centre and congenital infection status (Total N = 
705)
EXPOSURES Infection 
status
Odds ratio for abnormal developmental outcome (95% confidence interval)
Parent completed Child completed
Before birth CT+ CT- Motor Speech & language Behaviour Cognition 'Draw a Man' Line, circle, cross
1) Congenital toxoplasmosis 
(reference = uninfected)
178 525 1.35
(0.79, 2.30)
1.32
(0.75, 2.33)
1.10
(0.70, 1.73)
0.88
(0.37, 2.08)
0.94
(0.51, 1.74)
1.05
(0.53, 2.07)
2) Maternal age (yrs) 1*
<25 40 86 1.07
(1.02, 1.12)
0.93
(0.88, 0.99)
0.92
(0.87, 0.97)
0.97
(0.90, 1.05)
1.04
(0.99, 1.09)
1.00
(0.93, 1.07)
25–35 106 288
>35 27 35
3) Parity1*
0 40 179 1.00
(0.80, 1.24)
1.18
(0.94, 1.48)
0.97
(0.74, 1.27)
1.22
(0.93, 1.60)
0.96
(0.70, 1.31)
1.02
(0.74, 1.40)
= 1 72 212
Missing 66 136
4) Maternal education1
Primary 14 48 1.15
(0.89, 1.48)
0.58
(0.44, 0.77)
0.77
(0.63, 0.94)
0.74
(0.52, 1.05)
1.20
(0.87, 1.66)
1.01
(0.73, 1.38)
Secondary Lower 47 181
Secondary Upper 47 135
Further Education 66 152
Missing 4 11
5) Mother born outside country2
Yes 25 60 1.45
(0.74, 2.84)
2.30
(1.14, 4.63)
1.65
(0.92, 2.96)
2.25
(0.88, 5.78)
0.89
(0.39, 2.01)
1.66
(0.72, 3.83)
no (reference) 152 462
Missing 1 5
6) Child's gender2
Male (reference) 95 284 1.45
(0.74, 2.84)
0.81
(0.49, 1.36)
1.65
(0.92, 2.96)
2.25
(0.88, 5.78)
0.89
(0.39, 2.01)
1.66
(0.72, 3.83)
Female 83 232
Missing 0 11
7) Duration of prenatal 
treatment1 (mean wks, sd)
6.3
(6.5)
15.1
(12.2)
1.00
(0.98, 1.02)
1.02
(0.99, 1.05)
1.00
(0.98, 1.02)
0.99
(0.96, 1.02)
0.98
(0.96, 1.01)
1.00
(0.98, 1.03)
Missing 0 0
Exposures after birth
8) Child's age at 
questionnaire1 (months) 
Median, IQR
38
(37,40)
39
(38, 41)
0.81
(0.71, 0.93)
0.87
(0.77, 0.98)
0.98
(0.93, 1.04)
0.73
(0.56, 0.97)
0.88
(0.80, 0.97)
0.73
(0.60, 0.88)
Missing 0 1
1Odds ratio expresses risk of adverse developmental/behavioural outcome per unit increase in exposure, adjusted for centre and congenital 
infection status.
2Odds ratio expresses risk of adverse developmental/behavioural outcome, adjusted for centre and congenital infection statusPage 6 of 10
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more or less likely to have a child with clinical manifesta-
tions detected before 4 months of age (defined as micro-
phthalmia, microcephaly, seizures, abnormal or
suspicious neurological examination requiring referral to
a specialist, ventricular dilatation, or intracranial calcifica-
tion) and found no significant association (reported else-
where[7]). The association between neurological findings
and abnormal developmental and impairment scores will
be the subject of a further report. Nevertheless, a weakness
of the study is the response rate, which was lower for
uninfected than infected children.
Our analysis of reasons for non-response, found organiza-
tional attributes to be important determinants of
response. Centers that provided follow up themselves, or
had access to an address register, had better response rates
and, apart from congenital infection status, we found no
evidence of differential response rates according to other
patient characteristics.[7] Uninfected children were more
difficult to trace than infected children as they were dis-
charged from follow up in late infancy, whereas infected
children were followed indefinitely. However, we cannot
exclude the possibility that response was associated with
neurological problems more subtle than those detected in
Table 3: Factors associated with parental concerns, specialist referral, impact of behaviour on the family, and parental anxiety, at 3 
years, adjusted for centre and congenital infection status(Total N = 705)
Odds ratio for outcome (95% confidence interval)
EXPOSURES Any concerns5 Any referral Behaviour impact4 Parental anxiety3
Before birth
1) Congenital toxoplasmosis (reference = uninfected) 0.98 (0.95, 1.01) 2.00 (0.90, 4.45) 0.55 (0.22, 1.39) 3.01 (1.84, 4.94)
2) Maternal Age1 0.97 (0.92, 1.03) 0.96 (0.89, 1.05) 0.98 (0.90, 1.07) 0.98 (0.93, 1.03)
3) Parity1 0.96 (0.81, 1.15) 1.05 (0.72, 1.54) 0.98 (0.66, 1.44) 1.26 (1.06, 1.50)
4) Maternal Education1 0.91 (0.73, 1.14) 0.77 (0.51, 1.16) 1.18 (0.81, 1.74) 0.82 (0.65, 1.04)
5) Mother born outside country2 (no = reference) 1.59 (0.84, 3.01) 0.82 (0.18, 3.79) 2.20 (0.86, 5.60) 1.06 (0.51, 2.21)
6) Child's gender (male = reference) 1.89 (1.22, 2.93) 0.83 (0.39, 1.73) 0.99 (0.50, 1.96) 1.26 (0.81, 1.94)
7) Duration of prenatal treatment (wks) 0.98 (0.96, 1.00) 1.00 (0.96, 1.04) 1.01 (0.97, 1.05) 0.97 (0.94, 0.99)
After birth
8) Child's age at Questionnaire1 (month) 0.97 (0.90, 1.04) 1.07 (0.97, 1.19) 1.02 (0.93, 1.13) 0.97 (0.90, 1.04)
1Odds ratio expresses risk of adverse developmental/behavioural outcome per unit increase in exposure, adjusted for centre and congenital 
infection status
2Odds ratio expresses risk of adverse developmental/behavioural outcome, adjusted for centre and congenital infection status
3Adverse outcome defined by score corresponding most closely to the least able/most worried 10% in the uninfected children
4Adverse outcome defined by developers of SDQ questionnaire.
5Defined by answering 'yes' or 'a little' to question(s) about concerns.
Table 4: Factors associated with parent-reported impairment at 3 years adjusted for centre and congenital infection status (Total N = 
705)
Odds ratio for adverse outcome (95% confidence interval)
EXPOSURES Any visual impairment3 Hearing loss4 Neurological/mobility impairment5
Before birth
1) Congenital toxoplasmosis 2.22 (1.10, 4.49) 0.61 (0.26, 1.46) 1.88 (0.32, 11.04)
2) Maternal Age1 0.99 (0.92, 1.07) 0.91 (0.92, 1.07) 1.15 (0.94, 1.42)
3) Parity1 1.08 (0.82, 1.43) 0.77 (0.84, 0.99) 1.63 (1.01, 2.63)
4) Maternal Education1 1.13 (0.77, 1.65) 0.96 (0.67, 1.37) 0.70 (0.27, 1.79)
5) Mother born outside country2 (no = reference) 0.35 (0.08, 1.53) 0.54 (0.16, 1.87) Not estimable
6) Child's gender (male = reference) 1.76 (0.88, 3.51) 1.27 (0.64, 2.50) 0.78 (0.15, 3.98)
7) Duration of prenatal treatment (wks) 0.95 (0.92, 0.99) 1.01 (0.97, 1.04) 0.96 (0.87, 1.06)
After birth
8) Child's age at Questionnaire1 (month) 1.02 (0.93, 1.11) 0.90 (0.79, 1.03) 1.05 (0.86, 1.29)
1Odds ratio for effect of exposure on outcome in all subjects per additional unit increase in exposure variable, adjusted for centre 2Odds ratio for 
effect of exposure on outcome, adjusted for centre 3Defined as any visual impairment, including wearing glasses 4Defined as any intermittent or 
permanent hearing loss 5Defined as seizures requiring treatment, cerebral palsy, and/or impairedPage 7 of 10
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varied in infected and uninfected children.
A further weakness of the study is that we used only part
of the standardized assessment tool, or a modified version
of the tool, for all outcomes except behavior. This was
done to enhance response by reducing the questionnaire
to a reasonable length and average completion time of 21
minutes. Use of the full assessment tools, which would
have required considerable time to complete, may have
been more sensitive, but is unlikely to have been accepta-
ble to parents.[18] A further compromise was to assess
children at 3 years, rather than after school entry, when
mild to moderate impairment may be more readily
detected. Three years was decided because tracing
addresses would have become increasingly difficult with
age.
Our findings are consistent with the hypothesis that con-
genital toxoplasmosis either causes overt clinical damage,
or no abnormality, rather than a spectrum of neurological
impairment. However, further, more detailed assessments
at older ages, including clinician assessment designed to
detect mild or moderate impairment, are required to con-
firm or refute this hypothesis. An alternative interpreta-
tion is that the similarity in developmental outcomes in
infected and uninfected children is due to anti-toxo-
plasma treatment. However, we found no evidence that
the duration of prenatal treatment masked an adverse
effect of congenital toxoplasmosis, nor that treatment
caused adverse effects in uninfected children. We were
unable to explore the effect of postnatal treatment in this
analysis, although this will be investigated in a separate
report confined to infected children.
We found an increased risk of parent-reported visual
problems, which was largely due to reports of limited
vision. This difference may be overestimated as parents of
uninfected children were less likely to respond to this
(overall response rate 92%, only 1 infected child had no
response), and parents of infected children are likely to be
more concerned about vision. For the seven congenitally
infected children with limited vision, follow up by an
ophthalmologist at 3 or more years found normal vision
in 1 child, unilateral impaired vision in 5 children, and
bilateral blindness in one child (results to be reported in
detail elsewhere). Nevertheless, this finding concurs with
a long term follow up study (median age 6 years) of 327
infected children in Lyon. None of 79 infected children
with retinochoroiditis had bilateral visual
impairment[19].
Generalisability of our findings should be made with cau-
tion. Our cohort was from a European setting where
Table 5: Association between congenital toxoplasmosis and developmental outcomes: multivariable analyses
Developmental outcome (Odds ratio and 95% confidence interval)
PARENT COMPLETED
Motor Speech & language Behaviour Cognition
All centres (N = 705) 1.30 (0.75, 2.25)2 1.10 (0.60, 2.02) 3,4 1.05 (0.66, 1.67) 2 0.85 (0.35, 2.09)
Sensitivity analyses
a) France only (N = 379)1 1.22 (0.61, 2.42)2 0.98 (0.45,2.14) 1.15 (0.64, 2.09) 0.55 (0.17, 1.76)2
b) Poland only (N = 134) 1.10 (0.30, 4.06) 0.54 (0.13, 2.26) 0.94 (0.30, 2.92) 1.02 (0.16, 6.62)
c) Children aged 36 to <41 months (N = 553) 1.18 (0.68, 2.05) 1.04 (0.54, 2.00) 1.25 (0.70, 2.22) 0.61 (0.25, 1.50)
d) Children with no signs before 4 months (N = 538 Poland 
excluded)
1.08 (0.57, 2.07) 1.10 (0.51, 2.36) 1.02 (0.57, 1.82)2 0.35 (0.10, 1.24)
CHILD COMPLETED
'Draw a Man' Line, circle, cross
All centres (N = 705) 1.27 (0.66, 2.44)5 1.13 (0.56, 2.25)
Sensitivity analyses
a) France only (N = 379)1 0.77 (0.35, 1.67) 0.93 (0.40, 2.18)
b) Poland only (N = 134) 1.00 (0.17, 5.77) 0.76 (0.13, 4.41)
c) Children aged 36 to <41 months (N = 553) 0.79 (0.39, 1.63)5 0.96 (0.48, 1.95)
d) Children with no signs before 4 months (N = 538 Poland 
excluded)
0.96 (0.46, 2.02) 1.03 (0.45, 2.36)
All models include centre, maternal education, and child's age at completion of questionnaire
1adjusts for variability among centres relative to Lyon
2adjusted for maternal age
3adjusted for born outside the country
4adjusted for maternal age
5adjusted for gender, and maternal age squaredPage 8 of 10
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nal cohort, there were 21 terminations: 17 were for toxo-
plasmosis, and 8 of these occurred after a positive prenatal
diagnosis; 5 of the 8 underwent autopsy and 4 had
intracranial lesions or signs of disseminated infection.[6]
It is unlikely that, if these four babies had survived to three
years, the results for developmental and behavioural out-
comes would have been substantially altered. A further
possibility is that congenital toxoplasmosis may be more
severe in settings where the infecting organism load is
high, as has been hypothesized for postnatal acquired
infection[10]. For example, postnatal acquired ocular tox-
oplasmosis is both more common and more severe in Bra-
zil, and may be associated with acquisition of infection
from oocysts in unfiltered water[20]. Although a Brazilian
study found a similar risk of intracranial or ocular lesions
(17% of 47 infected children) to our European cohort
(20%: 51/255 infected children; personal communica-
tion, R Gilbert on behalf of EMSCOT), the study was con-
fined to women able to afford neonatal screening and
may not be representative of the risk in less affluent
communities[21].
Finally, the increased risk of anxiety may vary in different
settings. Parents of infected children are told that eye
lesions can appear at any age, and that such lesions may
cause loss of vision. How this message is presented, may
differ among clinicians. The effect of congenital infection
status on parental anxiety was most marked in Poland,
where the controls had not experienced screening, and
where there is no nationwide screening program. In con-
trast, the risk of anxiety was lowest in France. This may be
because parents are more familiar with congenital toxo-
plasmosis, and its limited clinical effects. Alternatively, it
may be that anxiety persists in parents of uninfected chil-
dren in France, thereby attenuating any difference. Mar-
teau has reported long term effects of false positive results
from other prenatal screening programs, highlighting per-
sisting perceptions among parents that 'something must
still be wrong'[9].
Conclusion
The purpose of prenatal and neonatal screening is to
reduce the risk of functional impairment. Apart from vis-
ual impairment, we found no evidence for adverse effects
of congenital toxoplasmosis on developmental outcomes,
behavior, or specific impairments by three years of age.
On average, infected children were no worse off, and there
was no evidence that this was because they received pre-
natal treatment. However, we could not examine the pos-
sibility that postnatal treatment ameliorated any
differences in function as all infected children were treated
in infancy. In addition, we cannot rule out the possibility
that we failed to detect more subtle differences that would
become apparent later in childhood. Finally, clinicians
need to explore ways for reducing the adverse effects of
diagnosis and follow up on parental anxiety. One
approach is to review whether they are being sufficiently
optimistic when counseling parents about prognosis.
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